Mylan's compelling product pipeline doesn't erase broader challenges in the generic drug industry.
Although we will make a few adjustments to our model, we don’t plan a change to our fair value estimate for Mylan, as the company’s fourth-quarter results and 2018 outlook mostly match our expectations. Our forecast for $12.5 billion in revenue and $5.47 in adjusted EPS for this year both fall near the midpoint of management’s guidance. After notching the recent generic Copaxone 40 mg approval, Mylan continues to have other compelling generic products in the pipeline, including the potential app...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.